Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients

Magréault, Sophie; Mankikian, Julie; Marchand, Sandrine; Diot, Patrice; Couet, William; Flament, Thomas; Grégoire, Nicolas

doi:10.1016/j.jcf.2019.08.027

Cited by 6 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be due to the limited use of polymyxin B compared with colistin in many hospitals due to non-availability and higher cost of polymyxin B. Though our patient was also on nebulised colistin, the systemic colistin levels with the use of nebulisation colistin are usually below quantification threshold, and unlikely to result in systemic toxicity 12 13…”

Section: Discussionmentioning

confidence: 91%

Polymyxin B-induced Bartter syndrome

Mohan Lal,

Musthafa Hafeesa,

Vikram

et al. 2024

BMJ Case Rep

View full text Add to dashboard Cite

Bartter syndrome is a genetic disorder characterised by chloride-unresponsive metabolic alkalosis, hypokalaemia, hypomagnesaemia and hypercalciuria. While it commonly presents antenatally or in early infancy, sometimes, drugs can induce a state similar to Bartter syndrome in any age group, called acquired Bartter syndrome. Polymyxins and aminoglycosides are the most commonly implicated drugs. Polymyxin B and polymyxin E (popularly known as colistin) are the two chemically similar polymyxins that are commonly used clinically. While colistin is frequently associated with nephrotoxicity, polymyxin B is generally considered less nephrotoxic. This difference is due to the way these two drugs are handled by the kidneys. In this case report, we discuss a middle-aged male who developed Bartter syndrome due to polymyxin B, which resolved on discontinuation of the drug, and re-appeared after its re-introduction later. This case exemplifies the nephrotoxicity caused by polymyxin B and the need for vigilance when using this drug.

show abstract

Section: Discussionmentioning

confidence: 91%

Polymyxin B-induced Bartter syndrome

Mohan Lal,

Musthafa Hafeesa,

Vikram

et al. 2024

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…For example, the local peak concentrations of aerosolized drugs could be different from those determined systematically after oral or intravenous administration. [84][85][86] The localized presence of mucins may locally negatively affect the antimicrobial efficacy and thus counteract the benefits of local delivery. [79] In fact, by providing the mucin content and the characteristic steric and interactive layers of mucus together with the presence of bacterial aggregates, CF-Mu 3 Gel closely reproduces the obstacles that antimicrobials must overcome to efficiently treat infections.…”

Section: Discussionmentioning

confidence: 99%

Heterogeneity Governs 3D‐Cultures of Clinically Relevant Microbial Communities

Peneda Pacheco,

Bertoglio,

Butnarasu

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

The intrinsic heterogeneity of bacterial niches should be retained in in vitro cultures to represent the complex microbial ecology. As a case study, mucin‐containing hydrogels ‐CF‐Mu3Gel ‐ are generated by diffusion‐induced gelation, bioinspired on cystic fibrosis (CF) mucus, and a microbial niche challenging current therapeutic strategies. At breathing frequency, CF‐Mu3Gel exhibits a G′ and G″ equal to 24 and 3.2 Pa, respectively. Notably, CF‐Mu3Gel exhibits structural gradients with a gradual reduction of oxygen tension across its thickness (280–194 µmol L−1). Over the culture period, a steep decline in oxygen concentration occurs just a few millimeters below the air–mucus interface in CF‐Mu3Gel, similar to those of CF airway mucus. Importantly, the distinctive features of CF‐Mu3Gel significantly influence bacterial organization and antimicrobial tolerance in mono‐ and co‐cultures of Staphylococcus aureus and Pseudomonas aeruginosa that standard cultures are unable to emulate. The antimicrobial susceptibility determined in CF‐Mu3Gel corroborates the mismatch on the efficacy of antimicrobial treatment between planktonically cultured bacteria and those in patients. With this example‐based research, new light is shed on the understanding of how the substrate influences microbial behavior, paving the way for improved fundamental microbiology studies and more effective drug testing and development.

show abstract

Unravelling the Hepatic Elimination Mechanisms of Colistin

Gijsen

Vocht

et al. 2023

Pharm Res

View full text Add to dashboard Cite

Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients

Cited by 6 publications

References 30 publications

Polymyxin B-induced Bartter syndrome

Polymyxin B-induced Bartter syndrome

Heterogeneity Governs 3D‐Cultures of Clinically Relevant Microbial Communities

Unravelling the Hepatic Elimination Mechanisms of Colistin

Contact Info

Product

Resources

About